Published on 2/17/2021 in the Prospect News Structured Products Daily.
New Issue: Credit Suisse sells $711,000 contingent coupon autocallable reverse converts on stocks
By Wendy Van Sickle
Columbus, Ohio, Feb. 17 – Credit Suisse AG, London Branch priced $711,000 of contingent coupon autocallable reverse convertible securities due Feb. 9, 2024 linked to the least performing of three stocks, according to a 424B2 filing with the Securities and Exchange Commission.
The stocks are DexCom, Inc., Edwards Lifesciences Corp. and Boston Scientific Corp.
Interest is payable quarterly at an 11.9% annual rate if each stock closes above its coupon barrier, 60% of its initial level, on the related observation date.
The notes will be called at par if the shares of the least performing stock close at or above their initial price on any quarterly trigger observation date.
The payout at maturity will be par unless any of the stocks finishes below its 60% knock-in level, in which case investors will receive a number of shares of the least performing stock equal to $1,000 divided by the initial share price or, at the issuer’s option, an amount in cash equal to the value of those shares.
Credit Suisse Securities (USA) LLC is the agent.
| Issuer: | Credit Suisse AG, London Branch
|
| Issue: | Contingent coupon autocallable reverse convertible securities
|
| Underlying stocks: | DexCom, Inc., Edwards Lifesciences Corp. and Boston Scientific Corp.
|
| Amount: | $711,000
|
| Maturity: | Feb. 9, 2024
|
| Coupon: | 11.9% per year, payable quarterly if each stock closes above coupon barrier on observation date
|
| Price: | Par
|
| Payout at maturity: | Par unless any stock finishes below knock-in price, in which case shares of least performing stock equal to $1,000 divided by initial share price or amount in cash equal to value of those shares
|
| Call: | At par if shares close at or above initial share price on any quarterly trigger observation date
|
| Initial prices: | $36.64 for Boston Scientific, $83.97 for Edwards Lifesciences, $394.63 for DexCom
|
| Coupon barriers: | $21.984 for Boston Scientific, $50.382 for Edwards Lifesciences, $236.778 for DexCom; 60% of initial levels
|
| Knock-in levels: | $21.984 for Boston Scientific, $50.382 for Edwards Lifesciences, $236.778 for DexCom; 60% of initial levels
|
| Pricing date: | Feb. 3
|
| Settlement date: | Feb. 9
|
| Agent: | Credit Suisse Securities (USA) LLC
|
| Fees: | 2.5%
|
| Cusip: | 22550MQK8
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
